Multiple cerebral infarctions associated with lung cancer-induced hypereosinophilia: a case report

Maki Ozaki1, Tomoo Mano1*, Nobuyuki Eura1, Kazuhide Horimoto2, Masato Takano3, Chiho Ohbayashi3 and Kazuma Sugie1

Abstract
Background: Hypereosinophilia (HE) is caused by various conditions, including solid and hematologic tumors. Nonetheless, there exist no reports on cerebral infarctions caused by HE associated with lung cancer metastasis to the bone marrow.

Case presentation: We report a case of a 67-year-old man with multiple cerebral infarctions associated with HE. His white blood cell and eosinophil counts were 38,900/μL and 13,600/μL, respectively, at 4 weeks before admission. During treatment for HE, he presented with dysarthria and walking difficulties. Magnetic resonance imaging of the brain showed multiple small infarcts in regions such as the bilateral cortex, watershed area, and cerebellum. Chest computed tomography showed small nodes in the lung and enlargement of the left hilar lymph nodes. Bronchoscopic biopsy did not reveal a tumor; however, bone marrow biopsy showed infiltration of tumor cells. We considered a diagnosis of lung cancer metastasizing to the bone marrow, which induced HE and later caused cerebral infarctions.

Conclusions: This case report demonstrates that metastatic cancer in the bone marrow can induce HE, which can consequently cause multiple cerebral infarctions. Clinicians should consider HE as a cause of multiple cerebral infarctions in patients with cancer.

Keywords: Hypereosinophilia, Lung cancer, Cerebral infarction, Watershed area

Background
Hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by a markedly elevated eosinophil count and is associated with the dysfunction of multiple organs. Secondary HES derives from various conditions such as autoimmune diseases, infections, solid cancer, and leukemia [1]. Hypereosinophilia (HE) is defined as an absolute eosinophil count of > 1.5 × 10^9/L on two examinations separated by at least 1 month and/or pathological confirmation of tissue HE. Organ damage-induced HE is defined as HES. Several reports on HE induced by solid and hematologic cancers such as paraneoplastic syndrome have been documented; nonetheless, it remains a rare condition. One of the mechanisms of HE is the production of several cytokines, including interleukin-3, interleukin-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF), by the primary cancer, which accounts for the increased production of eosinophilic granulocytes in the bone marrow. Another mechanism is an eosinophilotactic response due to necrosis in the tumor and increased production of eosinophils due to tumor cell dissemination in the bone marrow [2]. However, cases in which cancer bone

*Correspondence: manoneuro@naramed-u.ac.jp
1 Department of Neurology, Nara Medical University School of Medicine Graduate School of Medicine, 840 Shijo-Cho, Kashihara, Nara 634-8522, Japan
Full list of author information is available at the end of the article
metastasis itself induces HE are rare. Regardless of the cause, several patients with HE develop cerebral infarction, particularly in the watershed area. We report a case of a watershed area infarction due to HE caused by lung cancer metastasis to the bone marrow.

Case presentation
A 67-year-old man with type 2 diabetes mellitus presented to our hospital with an elevated white blood cell (WBC) count (38,900/μL) and eosinophil count (13,600/μL). He had no allergies or showed signs of infection. Malignancy was suspected, and some tumor markers were examined on the same day, including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19–9), neuron-specific enolase (NSE), progastrin-releasing peptide (ProGRP), squamous cell carcinoma (SCC), cytokeratin fragment (CYFRA), sialyl Lewis X-α antigen (SLX), and soluble interleukin-2 receptor (sIL-2R). sIL-2R concentration was remarkably elevated at 3421 IU/mL. To identify the cause of these hematologic abnormalities, chest computed tomography (CT) was performed, which revealed small nodes on both sides of the lungs and enlargement of the left hilar and right subclavian lymph nodes. Lung cancer metastasis to the bone marrow was suspected; thus, bronchoscopic biopsy and bone marrow biopsy were performed.

Four weeks later, he noticed weakness on both sides of his arms. He could not walk and speak well on the next day. Subsequently, he was admitted to our hospital at 2 days after the appearance of the first symptoms. On admission, the patient was 167 cm tall, and his body weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and his temperature was 36.9 °C. His conscious was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg. On examination, his blood pressure was 126/72 mmHg, his pulse was 79 beats per minute and weight was 53.3 kg.

On admission day, 2 days had already passed after the appearance of the first symptoms of infarction, and we could not carry out acute reperfusion therapy. Treatment was initiated with 50 mg/day of prednisolone for HE and 5000 units/day of unfractionated heparin for acute cerebral infarction (Fig. 2). We gradually increased the heparin dose to 8000 units/day to avoid APTT overextension. His eosinophil count slightly decreased, and simultaneognosia and oculomotor apraxia disappeared. Follow-up MRI of the brain on day 15 of admission showed no increase in infarcts; however, microbleeds in the infarcts were increased (Fig. 1e). We changed heparin to aspirin in consideration of hemorrhage.

On day 22 of admission, the pre-admission bronchoscopic biopsies revealed eosinophil infiltration of the bronchial epithelium and infiltration of cancer cells, eosinophils, and neutrophils into the bone marrow. Immunostaining of a bone marrow sample revealed the following pattern suggestive of lung adenocarcinoma: cytokeratin 7(+), cytokeratin 20(−), and thyroid transcription factor-1(+) (Fig. 3). He was diagnosed with clinical stage IVb lung adenocarcinoma.

We considered that the cerebral infarctions were caused by HE induced by lung cancer metastasis to the bone marrow. As warfarin is not appropriate for drug interaction, we then continued treatment with aspirin. On day 30, chemotherapy with pemetrexed for adenocarcinoma was initiated. We subsequently discovered that the elevation in D-dimer level was associated with deep vein thrombosis; hence, we changed the antithrombotic drug to warfarin. Despite chemotherapy and steroid therapy, the number of eosinophils did not decrease. Therefore, we tapered and then stopped the use of prednisolone.
**Fig. 1** MRI images. a-c Axial diffusion-weighted image and d fluid-attenuated inversion recovery of MRI show infarctions in the bilateral watershed area of the middle cerebral artery and the cerebellar hemispheres. e Follow-up susceptibility-weighted imaging on day 15 shows the increasing microbleeds in infarcts. MRI, magnetic resonance imaging.

**Fig. 2** Timeline. A timeline of the changes in eosinophil count and D-dimer levels with treatment is provided. After treatment was initiated with prednisolone for hypereosinophilia and unfractionated heparin for acute cerebral infarction, the eosinophil count was slightly decreased. Antithrombotic therapy was changed from heparin to aspirin previously, but the D-dimer level increased; therefore, it was changed to warfarin. Despite the chemotherapy and steroid therapy, his eosinophil count continued to increase, and his blood results indicated disseminated intravascular coagulation. Consequently, he died on day 57 of admission.
After the first round of chemotherapy, his WBC and eosinophil counts continued to increase, and his blood results indicated disseminated intravascular coagulation (DIC). His general condition deteriorated, and he died on day 57.

Discussion and conclusions
This case highlights a rare case of multiple cerebral infarctions associated with lung cancer metastasis-induced HE. There are several case reports on multiple cerebral infarctions due to ANCA-associated vasculitis [4–7]. Most of these cases presented with other clinical features (asthma, sinusitis, and skin rash) and were ANCA-positive. However, we did find a case of cerebral infarctions associated with ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) who had no clinical features [7]. This case was found to have granulomas with epithelial cells, eosinophilic infiltration, and vasculitis on autopsy. In our case, small nodes in the lung revealed on chest CT and a high serum sIL-2R level were suggestive of HE induced by a tumor rather than ANCA-associated vasculitis. After admission, the bone marrow biopsy revealed infiltration of tumor cells, and the patient had no clinical features of ANCA-associated vasculitis or other causes of HE. Therefore, we considered that the lung cancer metastasis to the bone marrow induced HE. We continued to administer therapy but did not add immunosuppressant agents such as rituximab and omalizumab.

There are several reports on HE caused by solid or hematologic tumors metastasizing to the bone marrow. Table 1 shows the reported cases of cancer metastasis to the bone marrow presenting with HE. The mechanism of HE development in association with cancer is hypothesized to be a paraneoplastic leukemoid reaction that stimulates the bone marrow via the production of tumor-produced cytokines, interleukin-5, and GM-CSF [8]. However, there is another hypothesis that an eosinophilic response occurs through necrosis of tumor cells disseminated in the bone marrow [2].

Table 1 Reported cases of hypereosinophilia secondary to cancer metastasis to the bone marrow

| Age  | Primary cancer       | Bone metastasis | Eosinophils (µL) | Cerebral infarction |
|------|----------------------|-----------------|------------------|---------------------|
| Todenhöfer et al., 2012 [2] | 46 | RCC | + | 21,636 | + |
| Akkad et al., 2020 [8] | 68 | NSCLC | + | 79,560 | + |
| Verstraeten et al., 2011 [9] | 65 | NSCLC | + | 41,040 | – |
| Evangeline et al., 2006 [10] | 72 | Thyroid carcinoma | + | 1600 | – |
| Our case | 67 | NSCLC | + | 47,481 | + |

NSCLC non-small cell lung carcinoma, RCC renal cell carcinoma
therapy, including glucocorticoids, hydroxyurea, and vincristine, is effective in reducing peripheral eosinophilic counts in paraneoplastic eosinophilia. However, in our case, neither steroid administration nor chemotherapy alleviated HE, and this became particularly evident in the biopsy results. Thus, we considered that the mechanism underlying HE development in this patient was not paraneoplastic; rather, it was eosinophilic. However, the exact mechanism of HE development in this patient could not be concluded.

Wu et al. reported that approximately 12% of patients with HES have cerebral infarctions [11]. Almost all cases of HE-induced cerebral infarctions were in the watershed area [12, 13], and our case is no exception. Infarctions in the watershed area are usually caused by hemodynamic mechanisms such as internal carotid artery stenosis or severe cardiac dysfunction. However, HE itself can induce an infarction in the watershed area. Therefore, MRI, particularly MRA, is very important for the examination of the etiology of watershed area infarctions [14].

Aida et al. reported that cerebral perfusion is lower in the watershed area than in the other areas of the brain. HE increases the consistency of blood and impairs clearance in this area [15]. Sarazin et al. reported that HE induces cardiomyopathy and causes microembolisms in the watershed areas [16]. In our case, we did not perform myocardial biopsy, but partial posterior left ventricular wall thickening was found on transthoracic echocardiography. This may be due to eosinophilic myocarditis, and we suspect that cardiac microthrombi may have caused microembolisms, which were not cleared in the watershed area.

According to the 2021 American Heart Association stroke guidelines, the potential beneficial effect of heparin on stroke prevention is unknown [17]. There exists no established medication treatment for cerebral infarctions in HE. However, empirically, antiplatelets and anticoagulants, including heparin, are frequently used because its etiology is thought to be both a hyperviscous state and microembolisms, which were not cleared in the watershed area.

In conclusion, we reported a case of multiple cerebral infarctions in the watershed area caused by cancer-induced HE. HE can sometimes cause cerebral infarction; however, there are few reports on cerebral infarction with HE caused by metastatic cancer in the bone marrow. HE should be considered as a cause of multiple cerebral infarctions in patients with cancer.

**Abbreviations**

ANCA: Antineutrophil cytoplasmic antibody; APTT: Activated partial thromboplastin time; BNP: Brain natriuretic peptide; CT: Computed tomography; CYFRA: Cytokeratin fragment; DIC: Disseminated intravascular coagulation; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HbA1c: Hemoglobin A1c; HE: Hypereosinophilia; HES: Hypereosinophilic syndrome; MRA: Magnetic resonance angiography; MRI: Magnetic resonance imaging; MPO-ANCA: Myeloperoxidase-antineutrophil cytoplasmic antibody; NSE: Neuron specific enolase; PR3-ANCA: Proteinase 3-antineutrophil cytoplasmic antibody; PT-INR: Prothrombin time-international normalized ratio; sL-2R: Soluble interleukin-2 receptor; SLX: Sialyl Lewis X-i antigen; WBC: White blood cell.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MO, NE, and TM conceived and designed the study. MO, NE, and TM drafted the manuscript. MO, NE, and KH examined, evaluated the patient and obtained the clinical data. MT and CO conducted the histopathological examination and interpreted them. KS participated in the design of the case-report and helped to draft the manuscript. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from Grants-in-Aid (KAKENHI No. 20K19453) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Ethical approval was not obtained for the publication of this case report, as this study does not share the personal details of the patient.

**Consent for publication**

Written informed consent for the publication of clinical details and/or clinical images was obtained from the next of kin of the patient.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Department of Neurology, Nara Medical University School of Medicine Graduate School of Medicine, 840 Shijo-Cho, Kashihara, Nara 634-8522, Japan. 2Second Department of Internal Medicine, Nara Medical University School of Medicine Graduate School of Medicine, 840 Shijo-Cho, Kashihara, Nara 634-8522, Japan. 3Department of Diagnostic Pathology, Nara Medical University School of Medicine Graduate School of Medicine, 840 Shijo-Cho, Kashihara, Nara 634-8522, Japan.

**Received:** 23 January 2021   **Accepted:** 29 September 2021

**Published online:** 13 October 2021

**References**

1. Valenti P, Klon AD, Horny HP, Roufosse F, Gottlib J, Weller PF, et al: Controversial consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607–12.e9.

2. Todenhöfer T, Wirths S, von Weyhern CH, Heckl S, Hunger M, Hennenlotter J, et al: Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma. BMC Urol 2012;12:7.

3. Razek AAKA, Elsebaie NA: Imaging of vascular cognitive impairment. Clin Imaging. 2021;74:45–54.

4. Cheng MJ, Huang PH, Liao PW, Chen JT, Chiang TR: Multiple cerebral and cerebellar infarcts as the first clinical manifestation in a patient with Churg-Strauss syndrome: case report and literature review. Acta Neurol Taiwanica. 2012;21:169–75.

5. Psychogios K, Evmorfidis I, Dragomanovits S, Stavridis A, Takis K, Kalamakis L, et al: ANCA-negative Churg-Strauss syndrome presenting as
acute multiple cerebral infarcts: a case report. J Stroke Cerebrovasc Dis. 2017;26:e47–9.
6. Maekawa K, Shibata M, Seguchi M, Kobayashi K, Naito Y, Miya F. Multiple cerebral infarctions due to patent foramen ovale in a patient with eosinophilic granulomatosis with polyangiitis. J Stroke Cerebrovasc Dis. 2018;27:e92–4.
7. Hira K, Shimura H, Kamata R, Takanashi M, Hashizume A, Takahashi K, et al. Multiple cerebral infarction diagnosed as eosinophilic granulomatosis with polyangiitis by autopsy. BMC Neurol. 2019;19:288.
8. Akkad N, Jiang Y, Shin D. Leukocytosis and stroke in a lung cancer patient. Eur J Case Rep Intern Med. 2020;7:001872.
9. Verstraeten AS, De Weerdt A, van Den Eynden G, Van Marck E, Snoeckx A, Jorens PG. Excessive eosinophilia as paraneoplastic syndrome in a patient with non-small-cell lung carcinoma: a case report and review of the literature. Acta Clin Belg. 2011;66:293–7.
10. Vassilatou E, Fisfis M, Morphopoulos G, Savvas S, Voucutsi E, Stefanoudaki K, et al. Papillary thyroid carcinoma producing granulocyte-macrophage colony-stimulating factor is associated with neutrophilia and eosinophilia. Hormones (Athens). 2006;5:303–9.
11. Wu X, Guo Y, Tan X. Acute cerebral infarction in watershed distribution in a patient with hypereosinophilic syndrome without cardiac lesion. Neurol Sci. 2014;35:1607–10.
12. Ishii J, Yamamoto S, Yoshimura H, Todo K, Kawamoto M, Kohara N. Multiple cerebral infarctions in a patient with hypereosinophilic syndrome with Loffler endocarditis: a case report. Rinsho Shinkeigaku. 2015;55:165–70.
13. McMillan HJ, Johnston DL, Doja A. Watershed infarction due to acute hypereosinophilia. Neurology. 2008;70:80–2.
14. Abdelrasoul AA, Elsebaie NA, Gamaledin OA, Khalifa MH, Razek AAAAA. Imaging of brain infarctions: beyond the usual territories. J Compt Assist Tomogr. 2019;43:443–51.
15. Aida L, Parkhutik V, Tembl JI, Martín N, Frasquet M, Bataller L. Embolism and impaired washout: a possible explanation of border zone strokes in hypereosinophilic syndrome. J Neurol Sci. 2013;325:162–4.
16. Sarazin M, Caumes E, Cohen A, Amarenco P. Multiple microembolic borderzone brain infarctions and endomyocardial fibrosis in idiopathic hypereosinophilic syndrome and in Schistosoma mansoni infestation. J Neurol Neurosurg Psychiatry. 2004;75:305–7.
17. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52:e364–467.
18. Navit BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and embolic stroke of undetermined source. Stroke. 2021;52:1121–30.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.